Business Context and Reporting Period
Company: Biorestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering and concurrent Private Placement.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $1.085 million (before fees and expenses).
- Shares Issued: 678,125 shares of common stock at $1.60 per share.
- Warrants Issued: 508,592 unregistered warrants to purchase common stock at an exercise price of $2.75 per share.
- Placement Agent Fees: 6% of gross proceeds from introduced investors (4% for others) plus reimbursement of approximately $8,300 in out-of-pocket expenses.
- Placement Agent Warrants: Warrants to purchase up to 6% of shares sold to introduced investors (4% for others) at $2.75 per share.
- Expected Closing Date: On or about October 8, 2025.
Material Changes and Use of Proceeds
This filing represents a new capital raise rather than a comparative financial period. The net proceeds are designated for:
- Clinical trials for the lead cell therapy candidate, BRTX-100.
- Pre-clinical research and development for the metabolic ThermoStem Program.
- Development of the commercial biocosmeceuticals platform.
- General corporate purposes and working capital.
Guidance, Risks, and Unusual Items
- Warrant Redemption: The Company may redeem unregistered warrants for $1.00 if the stock price exceeds $5.00 per share for ten consecutive trading days.
- Exercise Restrictions: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Cashless Exercise: If a registration statement is not in effect, holders may elect a cashless exercise.
- Regulatory Status: The private placement of warrants is conducted under Section 4(a)(2) and/or Rule 506(b) exemptions; these securities are not registered.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the dilution impact of the 678,125 new shares and the potential 508,592 warrant shares on existing shareholders.
- Review the full text of the Subscription Agreement (Exhibit 10.1) and Engagement Letter (Exhibit 10.2) for specific covenants.
- Monitor the status of the clinical trials for BRTX-100 to assess the efficacy of the capital deployment.
- Check for any subsequent filings regarding the exercise or redemption of the issued warrants.